Guideline History

Flowchart Imminent birth

F25.40.1-V4-R30

• Published: No change to clinical content. Review date updated.

Education presentation: Respiratory distress and CPAP

E24.3-1-V4-R29

• Published

Flowchart: Respiratory distress and CPAP

F24.3-1-V9-R29

• Published

Guideline and supplement: Respiratory distress and CPAP

MN24.3-V10-R29

• Published

Consumer information: Respiratory distress and CPAP

C24.3-1-V1-R29

• Published

Consumer information: Syphilis and pregnancy

C24.44-1-V3-R29

• Published

Consumer information: Syphilis in pregnancy and JHR

C24.44-2-V3-R29

• Published

Education presentation: Syphilis and pregnancy

E24.44-1-V6-R29

• Published

Flowchart: Newborn baby at risk of congenital syphilis

F24.44-2-V3-R29

• Published

Flowchart: Reactive serology or syphilis PCR positive

F24.44-3-V1-R29

• Published

Flowchart: Anental assessment for syphilis

F24.44-1-V6-R29

• Published

Flowchart: Syphilis and pregnancy approach to care

F24.44.4-V1-R29

• Published

Guideline and supplement: Syphilis and pregnancy

MN24.44-V7-R29

• Published

Scope for Prolonged and/or obstructed labour guideline development

SC24.17-1-V1-R29

• Published

Scope for review of Intrapartum fetal surveillance guideline

SC24.15-1-V1-R29

• Published

Scope for review of Gestational diabetes mellitus guideline

SC24.33-1-V3-R29

• Published

Maternity care for mothers and babies during COVID-19 pandemic

MN21.63-V12-R26

• Rescinded

Position statement: Gender associated language

O24.79-1-V1-R29

• New publication

Implementation checklist for guidelines

O24.35-1-V4-R29

• Published following review

Primary postpartum haemorrhage

MN24.1-V12-R29

• Amendment: deleted recommendation for Trendelenburg position if hypotensive during initial response to PPH

Neonatal medicine bevacizumab

NMedQ24.118-V1-R29

• New publication

Neonatal medicine atropine

NMedQ24.007.V2-R29

• Full review

Neonatal medicine hydroxocobalamin

NMedQ24.030-V2-R29

• Full review

Acute presentation of persistent pelvic pain

MN24.78-V1-R29

• New publication of guideline and supplement

Neonatal medicine aciclovir

NMedQ24.010-V4-R29

• Full review

Neonatal medicine meropenem

NMedQ24.009-V2-R29

• Full review

Neonatal medicine nirsevimab

NMedQ24.121-V1-R29

• New publication

Termination of pregnancy clinical guideline and supplement

MN24.21-V10-R29

• Publication following full review

Termination of pregnancy consumer information

C24.21-1-V4-R29

• Publication following full review to align with clinical guideline

Termination of pregnancy education presentation

E24.21-1-V7-R29

• Publication following full review to align with clinical guideline

Termination of pregnancy flowchart: Summary of termination of pregnancy

F24.21-1-V6-R29

• Publication following full review of clinical guideline

Termination of pregnancy flowchart: Medical termination at or less than 63 days

F24.21-2-V6-R29

• Publication following full review of clinical guideline

Neonatal medicine monograph: tetracaine

NMedQ24.003-V2-R29

• Publication following full review

Neonatal medicine monograph chloramphenicol

NMedQ24.029-V2-R29

• Publication following full review of neonatal medicine monograph

Publicly funded homebirth: consumer information

C24.77-1-V1-R29

• New publication to align with guideline

Primary postpartum haemorrhage flowchart Initial response to PPH

F24.1-1-V6-R29

• Publication to align with reviewed guideline

Primary postpartum haemorrhage flowchart: Massive haemorrhage protocol

F24.1-2-V5-R29

• Publication to align with reviewed guideline

Primary postpartum haemorrhage education presentation

E24.1-1-V6-R29

• Publication to align with reviewed guideline

Primary postpartum haemorrhage consumer information: severe bleeding after birth

C24.1-2-V3-R29

• Publication to align with reviewed guideline

Primary postpartum haemorrhage consumer information: bleeding after birth

C24.1-1-V7-R29

• Publication to align with reviewed guideline

Primary postpartum haemorrhage: guideline and supplement

MN24.1-V11-R29

• Publication following peer review

Hypoxic-ischaemic encephalopathy: guideline and supplement

MN21.11-V12-R26

• Amendment to guideline Table 15 to align with Flowchart: Passive cooling. From 34 degrees C to 33 degrees C

Neonatal medicine monograph procaine penicillin

NMedQ24.117-V1-R29

• First publication of neonatal medicine monograph procaine penicillin

Neonatal medicine monograph vitamin A

NMedQ24.116-V1-R29

• First publication of neonatal medicine monograph vitamin A

Flowchart: Assessment of location and viability in suspected early pregnancy loss

F22.29-4-V3-R27

• Amendment: to align with text in Table 9 of Early pregnancy loss guideline

Guideline and supplement: Early pregnancy loss

MN22.29-V7-R27

• Amendment: Flowchart Assessment of location and viability in early pregnancy loss: updated to align with text in Table 9

Guideline and supplement: Publicly funded homebirth

MN24.77-V1-R29

• First publication of the Publicly funded homebirth guideline and supplement

Education presentation: Publicly funded homebirth

E24.77-1-V1-R29

Education presentation to accompany the Publicly funded homebirth guideline and supplement

Consumer information: Perinatal mental health

C24.76-1-V1-R29

• First publication of consumer information to accompany the Perinatal mental health clinical guideline

Neonatal medicine monograph Sildenafil

NMedQ24.115-V1-R29

• First publication of neonatal medicine sildenafil

Consumer information: Instrumental vaginal birth

C24.49-1-V5-R29

• Following full review

Education presentation: Instrumental vaginal birth

E24.49-1-V3-R29

• Following full review

Guideline and supplement: Instrumental vaginal birth

MN24.49-V3-R29

• Following full review

Education presentation: Preconception and prenatal genetic screening

E24.36-1-V1-R29

• First publication

Flowchart Preconception reproductive genetic carrier screening

F24.36-1-V1-R29

• First publication

Flowchart Reproductive genetic carrier screening during pregnancy

F24.36-2-V1-R29

• First publication

Flowchart Chromosome condition screening during pregnancy

F24.36-3-V1-R29

• First publication

Guideline and Supplement: Preconception and prenatal genetic screening

MN24.36-V1-R29

• First publication

Flowchart: Management of women with Rh D negative blood group (including NIPA)

F23.74-2-V2-R28

• Amended: - termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

Flowchart: Management of women with Rh D negative blood group (excluding NIPA)

F23.74-1-V2-R28

• Amended: - termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

Education presentation Rh D negative women in pregnancy

E23.74-1-V2-R28

• Amended: - termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

Guideline and supplement: Rh D negative women in pregnancy

MN23.74-V2-R28

• Amended: Termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

Perinatal mental health

E24.76-1-V1-R29

• First publication of education presentation to accompany the Perinatal mental health clinical guideline

Perinatal mental health

F24.76-1-V1-R29

• First publication of flowchart to accompany the Perinatal mental health clinical guideline

Perinatal mental health

MN24.76-V1-R29

• First publication of Perinatal mental health clinical guideline and supplement

Neonatal medicine monograph hydralazine hydrochloride

NMedQ24.111-V1-R29

• First publication of neonatal medicine monograph hydralazine hydrochloride

Neonatal medicine monograph phosphate

NMedQ22.087-V2-R27

• Deleted: compound oral solution is no longer available and was deleted

Neonatal medicine monograph vitamin D

NMedQ22.075-V2-R27

• Amendment: dosage for neonatal deficiency added

Neonatal medicine monograph phenobarbital

NMedQ21.062-V2-R26

• Amendment: duration of IV administration (infusion and injection) added

Neonatal medicine monograph isradipine

NMedQ24.113-V1-R29

• First publication of the neonatal medicine monograph isradipine

Neonatal medicine monograph sprionolactone

NMedQ24.112-V1-R29

• First publication of the neonatal medicine monograph spironolactone

Working party list for Newborn bloodspot screening

WP24-53-1-V1-R29

• List of working party members for the Newborn bloodspot screening guideline

Parent information Perineal care

C23-30-1-V5-R28

• "Your perineum and having a baby" parent information to accompany the Perineal care clinical guideline

Parent information Perineal care

C23-30-2-V6-R28

• "Third and fourth degree tears" parent information to accompany the Perineal care clinical guideline

Neonatal medicine monograph benzyl-penicillin

NMedQ20.013-V5-R25

• Added: definition of current gestational age
• Amended: instructions for dose frequency to clarify frequency alters as baby ages
• Added: duration of dosage for congenital syphilis

Neonatal medicine monograph albumin

NMedQ20.048-V2-R25

• Amendment: added albumin 5% for Australian transition from 4% to 5% albumin
• Updated: albumen 20% product name and storage conditions

Neonatal medicine monograph morphine sulfate

NMedQ20.032-V2-R25

• Amendment: Added to special considerations: "If prescribed as premedication for elective intubation, wait at least 5 minutes (5–15 minutes) for onset of action before administration of subsequent medications"
• Removed: UAC icon and amended instructions for administration via UAC

Term prelabour rupture of membranes (PROM-Term)

C23.47-1-V2-R28

• Publication of consumer information to accompany the peer review of guideline and supplement

Term prelabour rupture of membranes (PROM-Term)

E23.47-1-V3-R28

• Publication of education to accompany the peer review of guideline and supplement

Term prelabour rupture of membranes (PROM-Term)

MN23.47-V2-R28

• Publication of of guideline and supplement following peer review

Preterm prelabour rupture of membranes (PPROM)

MN23.48-V3-R28

• Publication of guideline and supplement following peer review

Preterm prelabour rupture of membranes (PPROM)

E23.48-V3-R28

• Publication of education to accompany the peer review of guideline and supplement

Preterm prelabour rupture of membranes (PPROM)

C23.48-1-V3-R28

• Publication of consumer information to accompany the peer review of guideline and supplement

Perineal care

MN23.30-V5-R28

• Publication of guideline and supplement following peer review

Perineal care

E23.30-1-V4-R28

• Publication of education to accompany the peer review of the perineal care clinical guideline

Neonatal medicine monograph Indometacin

NMedQ23.104-V1-R28

• First publication of the neonatal medicine Indometacin

Neonatal medicine monograph Glucose gel

NMedQ19.020-V2-R24

• Amendment: Added indication and dose for prophylactic use and a quick guide for dose by weight calculation

Stabilisation for retrieval-neonatal

E23.18-1-V6-R28

• Publication: Education presentation to accompany stabilisation for retrieval clinical guideline and supplement

Stabilisation for retrieval-neonatal

C23.8-1-V5-R28

• Publication: Consumer information to accompany stabilisation for retrieval clinical guideline and supplement

Stabilisation for retrieval-neonatal

MN23.18-V5-R28

• Publication: Peer review of guideline and supplement

Hypoglycaemia - newborn

C23.8-1-V5-R28

• Publication: Consumer information to accompany the hypoglycaemia -newborn clinical guideline

Hypoglycaemia - newborn

E23.8-1-V6-R28

• Publication: Education presentation to accompany the full review of the hypoglycaemia -newborn clinical guideline

Hypoglycaemia - newborn

MN23.8-V13-R28

• Published: Full review of clinical guideline and supplement

Stillbirth care

MN23.24-V10-R28

• Amendment: Updated reference to QLD Maternal and Perinatal Quality Council report
• Amendment: Updated reference to Hospital and Health Services Act

Termination of pregnancy

Ed19.21-1-V6-R24

• Amendment: Updated to align with guideline MN19.21-V9-24. Minor wording about capacity to consent

Termination of pregnancy

F19.21-2-V5-R24

• Amendment: Updated to align with guideline MN19.21-V9-24. Requirement for prescriber education for MS-2 Step removed

Termination of pregnancy

MN19.21-V9-R24

• Amendment: Removed requirements for MS-2 Step prescriber education as per TGA
• Amendment: Section 5.4 Fetal considerations - new section (section 5.4.3 Born with signs of life) inserted
• Amendment: Section 5.3 MToP and SToP risks and complications - Live birth added

Stillbirth care

E23.24-1-V8-R28

• Publication of education presentation to accompany the Stillbirth care guideline

Stillbirth care

C23.24-2-V7-R28

• Publication of consumer information 'Autopsy examination of a baby' to accompany the Stillbirth care guideline

Stillbirth care

C23.24-1-V7-R28

• Publication of consumer information 'What to expect after the loss of your baby' to accompany the Stillbirth care guideline

Stillbirth care

C23.24-3-V3-R28

• Publication of consumer information 'Grief after your baby dies' to accompany the Stillbirth care guideline

Stillbirth care

MN23.24-V9-R28

• Publication of Stillbirth care clinical guideline and supplement following Peer Review

Neonatal medicine miconazole

NMedQ23.107-V1-R28

• First publication of neonatal medicine miconazole

Neonatal medicine glycerol

NMedQ23.108-V1-R28

• First publication of neonatal medicine glycerol

Neonatal medicine microlax

NMedQ23.103-V1-R28

• First publication of neonatal medicine microlax

Neonatal medicine nystatin

NMedQ23.100-V1-R28

• First publication of neonatal medicine nystatin

Instrumental vaginal birth

MN18.49-V2-R23

• Review date extended until Dec 2024. No change to content

Perineal care

MN18.30-V4-R23

• Review date extended until Dec 2024. No change to content

Primary postpartum haemorrhage

MN18.1-V10-R23

• Review date extended until Dec 2024. No change to content

Syphilis in pregnancy

MN18.44-V6-R23

• Review date extended until Dec 2024. No change to content

Syphilis in pregnancy

MN18.44-V6-R23

• Amendment: To align with QMPQC recommendations for routine antenatal screening at 36 weeks

Fetal movements

MN23.46-V3-R28

• Peer review
• Formatting and references updated

Normal birth

MN22.25-V5-R27

• Amendments to Section 2.1 Continuity of care: Statistical analysis in Tables 4 and 5 amended from Absolute Risk Reduction/Absolute Benefit Increase to;Risk Ratio.

Induction of labour

MN22-22-V9-R27

• Update: Statistics in Table 5, Table 6, Table 13 and Table 23 updated
• Addition to Flowchart: Oxytocin and Appendix D: Oxytocin regimen administration: Caution note and suggested maximum oxytocin dosage for use in women with previous uterine surgery added

Establishing breastfeeding

MN21-19-V5-R26

• Amendment: Section 6. Recommended time frame to express breasts if baby unable to initiate breastfeeding or is separated from mother-changed from within six hours of birth, to within two hours of birth
• Amendment: Appendix D: Breast engorgement and mastitis spectrum sections updated

Neonatal medicine dexmedetomidine

NMedQ23.101-V1-R28

• First publication of neonatal medicine dexmedetomidine

Neonatal medicine trimethoprim with sulfamethoxazole

NMedQ23.106-V1-R28

• First publication of neonatal medicine trimethoprim with sulfamethoxazole

Neonatal medicine heparin sodium

NMedQ23.102-V1-R28

• First publication of neonatal medicine heparin sodium

Neonatal medicine omeprazole

NMedQ23.105-V1-R28

• First publication of neonatal medicine omeprazole

Clinical form: Neonatal seizure and neurological observations

SW1209-V1

• First publication of clinical form for neonatal seizure and neurological observation

Clinical form: Encephalopathy servity assessment and therapeutic cooling critiera

SW1208-V1

• First publication of clinical form for encephalopathy severity assessment and therapeutic hypothermia criteria

Education presentation: Neonatal resuscitation

E22.5-1-V6-R27

• Amendment to education presentation to clarify chest compression techniques to be used if one or two person performing

Working party list: Fetal movements

WP23.46-1-V2-R28

• List of working party members for review of fetal movements

Education presentation: Rh D woman and pregnancy

E23.74-1-V1-R28

• New publication education presentation

Consumer information: Rh D woman and pregnancy

C23.74-1-V1-R28

• New publication consumer information sheet

Neonatal medicine benzylpenicillin

NMedQ20.013-V4-R25

• Amendment to align with ASID recommendations for term infants: Dosage for sepsis (IV and IM) for baby at 37+0 weeks or more current gestational age at 8 or more days of age FROM 60 mg/kg every 8 hours TO 60mg/kg every 6 hours.

Neonatal medicine clonidine

NMedQ22.085-V2-R27

• Amendment: Preparation instructions for tablet use added

Term small for gestational age baby

MN22-16-V6-R27

• Amendment: Correction Table 9. Estimate of growth restriction using Fenton growth charts - Female weight at 41+0 weeks gestation on 10th percentile FROM 3980 g TO 2980 g

Retinopathy of prematurity consensus statement

O21.55-1-V2-R26

• Amendment: Added for further information refer to RANZCO guideline

List of working party members for Stillbirth care review

WP23.24-1-V1-R28

• Working party members for Stillbirth care review

Guideline: Rh D negative women and pregnancy

MN23.74-V1-R28

• New publication clinical guideline and supplement

Consumer information: Breastfeeding and medicines

C23.19-2-V1-R28

• New publication to accompany breastfeeding clinical guideline

Consumer information: Induction of labour (IOL)

C23.22-1-V4-R27

• Accompany IOL clinical guideline

Consumer information: Induction of labour (IOL): Part 1 cervical ripening

C23.22-2-V1-R27

• New publication to accompany IOL clinical guideline

Consumer information: Induction of labour (IOL): Part 2 rupturing your membranes and oxytocin

C23.22-3-V1-R27

• New publication to accompany IOL clinical guideline

Guideline: Intrapartum pain management

MN23.75-V1-R28

• First publication of clinical guideline on intrapartum pain management and associated resources
• Incorporated existing 4 shortGuides on pharmacological analgesia (now rescinded)

Neonatal medicine poloxamer 10%

NMedQ23.099-V1-R28

• First publication of neonatal medicine poloxamer 10%

Neonatal medicine palivizumab

NMedQ23.098-V1-R28

• First publication of neonatal medicine palivizumab

Neonatal medicine rasburicase

NMedQ23.097-V1-R28

• First publication of neonatal medicine rasburicase

Neonatal medicine levothyroxine

NMedQ23.096-V1-R28

• First publication of neonatal medicine levothyroxine

Guideline Stillbirth care

MN18.24-V8-R23

• Review date extended while review in progress. Nil other amendments

Guideline Neonatal stabilisation for retrieval

MN18.18-V4-R23

• Review date extended while review in progress. Nil other amendments

Eduction presentation Gestational diabetes mellitus

E21.33-1-V3-R26

• Amendment slide 23 Metformin: Maximum dose metformin: FROM 2500 mg standard release (SR) TO: Metformin 2500 mg intermediate release (IR)

Neonatal medicine Adrenaline

NMedQ22.079-V4-R27

• Amendment: Added to ETT dose: volume equivalent in mL/kg

Neonatal medicine Caffeine Citrate

NMedQ19.006-V2-R24

• Added to preparation instructions: prescribed dose greater than 0.5 mL (10 mg) may be given undiluted
• Added to special considerations: small dose volumes can be difficult to administer accurately to VLBW infants therefore diluted preparation is the preferred option in this cohort
• Added to signs of toxicity: tremors and tachypnoea
• Added QR code
• Deleted UAC icon: wording amended about administration via UAC
• Minor referencing updates

Neonatal medicine Vancomycin

NMedQ23.094-V1-R28

• First publication of neonatal medicine vancomycin

Neonatal medicine Valganciclovir

NMedQ23.093-V1-R28

• First publication of neonatal medicine valganciclovir

Neonatal medicine Ganciclovir

NMedQ23.092-V1-R28

• First publication of neonatal medicine ganciclovir

Neonatal medicine Fluconazole

NMedQ23.095-V1-R28

• First publication of neonatal medicine fluconazole

Neonatal medicine Adrenaline

NMedQ22.079-V3-R27

• Amendment: Correction to IV infusion preparation instructions. FROM: Draw up 0.3 mg/kg (0.3 mL/kg of 1:10,000) TO: Draw up 0.3 mg/kg (3 mL/kg of 1:10,000)s

Termination of pregnancy

MN19.21-V8-R24

• Amendment: For MS-2 Step: FROM undertake routine antenatal serum screening. TO: If MToP with MS-2 Step, routine antenatal serum screening not required, consider based on history/opportunistically with other serum tests

Neonatal jaundice

MN22.7-V9-R27

• Full Review
• Removed: Elements of care relevant to QCG 'Standard care' clinical guideline
• Removed: Nomograms referenced to QCG 'Nomograms for jaundice phototherapy and exchange transfusion'

Neonatal seizures

MN22.23-V4-R27

• Full Review
• Removed: Elements of care relevant to QCG 'Standard care' clinical guideline
• Removed: Drug regimens referenced to QCG 'NeoMedQ neonatal medicine monographs'
• Updated: Classification of seizures as per International League of Epilepsy

Induction of labour

MN22.22-V8-R27

• Full Review
• Expanded: Guidance on communication and decision making, timing of birth, risks and benefits of IOL compared with expectant management, setting for cervical ripening
• Updated: prolonged pregnancy, suspected fetal macrosomia, intrahepatic cholestasis, advanced maternal age, transcervical balloon catheter

Normal birth

MN22.25-V4-R27

• Full Review
• Removed: Elements of care relevant to 'Standard care' clinical guideline
• Transferred to 'Intrapartum pain management' clinical guideline: Pharmacological and non pharmacological support including water immersion, and nitrous oxide and oxygen

Preterm labour and birth

MN20.06-V10-R25

• Flowchart MgSO4: Amendment - loading dose aligned with text FROM over 15 minutes | TO over 20 minutes
• Table 2. Risk factors associated with preterm birth: Addition - risk of PTB based on ethnicity
• Table 3 Risk reduction measures: Addition - recommendation for universal routine cervical length measurement during mid-trimester ultrasound
• Section 3.1 Progesterone therapy: Amendment - recommendation strengthened FROM Consider prophylactic progesterone | TO Recommend vaginal progesterone from 16-36 weeks if incidentally diagnosed shortened cervix or prior spontaneous preterm birth between 20–34 weeks
• Section 3.2 Cervical cerclage: Addition - consider cervical cerclage for women with cervical length less than 10 mm
• Section 5.4 Antenatal corticosteroids: Amendment - recommendations aligned with QCG guideline: Antenatal corticosteroids

Standard care

MN22.50-V2-R27

• Guideline and supplement (Full Review)

Pain and bleeding in early pregnancy

C22.29-2-V4-R27

• New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

Having a miscarriage

C22.29-4-V1-R27

• New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

Ectopic pregnancy

C22.29-1-V2-R27

• New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

Methotrexate for ectopic pregnancy

C22.29-5-V1-R27

• New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

Neonatal resuscitation checklist

F22.5-3-V3-R27

• Amendment: Added additional equipment when humidification required (adaptor 15m/10f-10m neonatal; humidification T-piece circuit;humidifer chamber; sterile water for injection 1L bag)

Hypoxic ischaemic encephalopathy

MN21.11-V11-R26

• Amendment: Table 6 HIE staging, to align with Flowchart Assessing baby for therapeutic hypothermia FROM: If three or more signs of moderate or severe HIE or seizures at any time in first six hours consult with neonatologist regarding commencing TH. TO: If two or more signs of moderate or severe HIE or seizures at any time in first six hours consult with neonatologist regarding commencing TH

Termination of pregnancy

MN19.21-V7-R24

• Amendment: Rh D immunoglobulin no longer recommended for MToP before 10+0 weeks gestation
• Amendment: Recommendation for prophylactic antibiotics for MToP changed FROM: Insufficient evidence to recommend the use of antibiotics prior to MToP TO: Prophylactic antibiotics not recommended for MToP
• Added: Information when counselling women about the potential for live birth

Syphilis in pregnancy

MN18.44-V5-R23

• Amendment: Universal screening at 28 weeks gestation recommended

Early pregnancy loss

MN22.29-V6-R27

• Guideline and associated resources: Peer review

Neonatal resuscitation

MN22.5-V6-R27

• Guideline and associated resources: Peer review

Neonatal medicine pyridoxine

NMedQ22.089-V1-R27

• First publication neonatal medicine pyridoxine

Neonatal medicine phenytoin

NMedQ22.090-V1-R27

• First publication neonatal medicine phenytoin

Neonatal medicine lidocaine

NMedQ22.091-V1-R27

• First publication neonatal medicine lidocaine

Neonatal medicine clonazepam

NMedQ22.088-V1-R27

• First publication neonatal medicine clonazepam

Adult inpatient management of steroid induced hyperglycaemia

ACG22.73-1-V1-R27

• First publication (in collaboration with Queensland Diabetes Clinical Network)

Early onset Group B Streptococcal disease

MN22.20-V6-R27

• Flowchart: Neonatal management of early onset Group B Streptococcal disease (EOGBSD) updated to reflect text
• Section 2 Risk factors: FROM another baby of multiple | TO other baby of multiple
• Section 5.2 Criteria for investigation of sepsis: increased observation – removal of preterm labour at less than 37+0 weeks
• Section 5.2 Criteria for investigation of sepsis: increased observation – addition of guidance for monitoring newborn with sibling currently treated for GBS infection
• Section 5.4 Antibiotic therapy: FROM treatment of GBS meningitis for diagnosed infection | TO guidance for treatment of both confirmed and suspected GBS meningitis

Aciclovir

NMedQ19.10-V3.R24

• Amendment to preparation instructions: powdered vial no longer available

Safer infant sleep

MN22.71-V1-R27

• First publication (in collaboration with QLD Paediatric Quality Council)

Early onset Group B Streptococcal disease

MN22.20-V5-R27

• Peer Review: Risk factor approach re-endorsed

Neonatal medicine adrenaline (epinephrine)

NMedQ22.079-V2-R27

• Amendment: to align with ANZCOR recommendation for rapid IV bolus during resuscitation. FROM: Adrenalin every 2–3 minutes TO: Adrenaline every 3–5 minutes

Neonatal medicine phosphate

NMedQ22.087-V1-R27

• First publication neonatal medicine phosphate

Neonatal medicine magnesium sulfate

NMedQ22.086-V1-R27

• First publication neonatal medicine magnesium sulfate

Neonatal medicine clonidine

NMedQ22.085-V1-R27

• First publication neonatal medicine clonidine

Neonatal medicine azithromycin

NMedQ22.084-V1-R27

• First publication neonatal medicine azithromycin

Neonatal medicine argipressin (vasopressin)

NMedQ22.083-V1-R27

• First publication neonatal medicine argipressin

Hypoglycaemia - newborn

MN19.8-V12-R24

• Amendments Flowchart 3: Management of neonatal hypoglycaemia (baby symptomatic or BGL 1.5 mmol/L
  • Renamed TO Management of BGL less than 1.5 mmol/L or baby symptomatic,
  • Amended criteria for commencement of weaning IV therapy to align with document text
    • FROM BGL 2.6 mmol/L for more than 12 hours
    • TO BGL 3.0 mmol/L for more than 12 hours.
  • Duplicate label on outflow amended FROM yes TO no
  • Urgent treatment:
    • FROM If asymptomatic or mild symptoms: Administer IV 10% glucose bolus, Consider glucose gel 40% and breastfeed in addition, Commence 10% glucose infusion at 60 mL/kg, Give glucagon IM or subcut if IV access delayed by more than 15 minutes -If symptomatic or BGL not improving: Give glucagon IV (IM or subcut if IV access delayed by more than 15 minutes), Commence 10% glucose infusion at 80 mL/kg
    • TO Commence 10% glucose infusion at 60 mL/kg/day, If symptomatic or BGL not improving commence at 80 mL/kg/day; Give 10% glucose 1–2 mL/kg IV bolus Consider glucose gel 40% and breastfeed, Recheck BGL after 30 minutes, If BGL improving, continue 10% glucose IV adjust as needed, If symptomatic or BGL not improving give glucagon IV, Repeat BGL after 30 minutes and if required, repeat glucose bolus and glucagon, If IV access delayed > 15 minutes give glucagon IM or subcut.
• Added to Definitions: enteral feeding
• Table 5 Screening:
  • Last row split into two rows (new row: Validate BGL less than 2.6 mmol/L) no content change
• Table 8: Initial management (first 48 hours of life)
  • References to NeoMedQ monographs rationalised to top of page
  • Third row (BGL less than 1.5 mmol/L or unrecordable) spilt into two rows (new row Difficult IV access) no content change
  • Last row: (Ceasing BGL monitoring) moved to new table: Ceasing BGL monitoring
• Table 11: BGL monitoring First row (BGL)
  • Split into 5 rows (no content change)
  • Last row (Ceasing BGL monitoring) moved to new table: Ceasing BGL monitoring
• Table 12: Ceasing BGL monitoring
  • New table from content in Table 8 and Table 11
  • Correction to criteria for ceasing after 48 hours
    • FROM 3 mmol/L TO 3.3 mmol/L
• Subsequent table numbering increased by 1
• Table 15: Medications
  • References updated to relevant NeoMedQ medicine monographs only
• Minor formatting corrections throughout

Gestational diabetes mellitus

MN21.33-V7-R26

• Flowchart: Screening and diagnosis of GDM - amended: information from guideline (Table 16 Self-monitoring) about fasting BGL and commencement of pre- and postprandial self-monitoring (when OGTT not suitable)

Neonatal medicine topiramate

NMedQ21.067-V2-R26

• Deleted from special considerations “if therapeutic hypothermia refer to QCG Neonatal seizures guideline”

Neonatal Seizures

MN17.23-V3-R22

• Review date extended FROM May 2022 TO May 2023

Early pregnancy loss

MN17.29-V5-R22

• Review date extended FROM May 2022 TO May 2023

Induction of labour

MN17.22-V7-R22

• Review date extended FROM March 2022 TO March 2023

Gestational diabetes mellitus

MN21.33-V6-R26

• Flowchart: Screening and diagnosis of GDM - added: information from guideline (Table 16 Self-monitoring) for suggested target BGLs when self-monitoring
• Flowchart Screening and diagnosis of GDM and Tables 8 and 14: - FROM: ‘evidence of fetal hyperinsulinaemia on growth USS’. TO: ‘evidence of excess fetal growth/adiposity on growth USS’
• Table 20 Metformin FROM: Maximum dose: 2500mg (SR) TO: Maximum dose: 2500mg (immediate release) (no dose change)

Statewide nomograms forms (all)

SW1106 to SW1111 (V2)

• Update (all): additional fields to capture start and end time of phototherapy

Maternity care for mothers and babies during the COVID-19 pandemic

MN21.063-V12-R26

• Guideline, supplement and flowchart: Updated information about close contact management. Update to COVID-19 vaccination intervals after positive COVID-19 result.

Neonatal medicine vitamin D

NMedQ22.075-V2-R27

• Added: information if receiving low birth weight formula or human milk fortifier and commencement if no previous pentavite.

Preterm prelabour rupture of membranes (PPROM)

MN18.48-V2-R23

• Guideline and education: Recommended antibiotics for PPROM updated and aligned with Therapeutic Guidelines.